Skip to content

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306) 1

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306). This study is ongoing, but not recruiting participants. A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306). This study is ongoing, but not recruiting participants. 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306).

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306) 2A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306). 122 0551 is a novel topical formulation of an unspecified corticosteroid that is being developed by Therapeutics Incorporated for the treatment of skin. Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306) (Therapeutics, Inc.) View Original at ClinicalTrials.gov. A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis. 3 study (Study 306) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis. A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants.

A Comparison Of 122-0551 Foam Versus Vehicle Foam In Subjects With Plaque Psoriasis (study 306)

Trial Sponsors